乙肝疫苗市场规模（按类型、患者类型、分销管道、地区、范围和预测）

乙肝疫苗市场规模及预测

预计 2024 年乙肝疫苗市场规模将达到 82.6 亿美元，到 2032 年将达到 133.1 亿美元，2026 年至 2032 年的复合年增长率为 4.6%。

乙肝疫苗用于预防感染B肝病毒，B肝病毒可导致肝硬化和肝细胞癌等严重的肝病。

这些疫苗透过刺激人体免疫系统产生针对B肝病毒的抗体来发挥作用。

此外，乙肝疫苗广泛应用于新生儿和高风险成人族群的国家免疫计划，被认为是预防B型肝炎感染及其併发症最有效的方法之一。

乙肝疫苗市场动态

关键市场驱动因素

全球乙肝感染率上升：全球乙肝感染率上升是疫苗接种需求成长的主要驱动因素。根据世界卫生组织 (WHO) 的数据，2019 年全球约有 2.96 亿人患有慢性B肝，每年新增感染人数达 150 万人。感染人数的上升凸显了接种疫苗以防止疾病进一步传播的必要性。

政府免疫接种计划：许多国家已扩大其疫苗接种计划，以对抗B型肝炎感染，市场规模也大幅扩张。例如，在美国，疾病预防控制中心 (CDC)建议所有婴儿、19 岁以下未接种疫苗的儿童以及高风险成年人接种B型肝炎疫苗。到 2020 年，全球婴儿疫苗接种覆盖率将达到 85%，而 2000 年仅为 30%。

医疗保健意识提升和倡议：在新兴国家，人们对B型肝炎的认识正在不断提高，政府主导的卫生计画正在推广疫苗接种。例如，中国国家卫生健康委员会已启动一项倡议，旨在透过加强疫苗接种来降低慢性B型肝炎的盛行率。根据2020年的一项研究，中国超过90%的儿童在一岁前接种了B型肝炎疫苗，这对市场成长至关重要。

主要挑战

疫苗犹豫：儘管乙肝疫苗的有效性已被证实，但疫苗犹豫在某些地区仍然是一个重大挑战。对疫苗安全性和有效性的误解可能会阻碍疫苗接种率，并影响市场成长。

低温运输管理：B型肝炎疫苗在储存和运输过程中需要严格的温度控制。维护低温运输带来物流挑战，尤其是在资源匮乏的地区，这会影响疫苗的分发和取得。

研发新疫苗高成本：开发新型改良B肝疫苗需要大量的研发成本。高成本阻碍了新进入者进入市场，并限制了该领域的创新。

主要趋势：

更重视成人疫苗接种：儘管儿童疫苗接种计画已经很完善，但人们越来越重视成人B型肝炎疫苗接种。这种趋势源自于人们认识到许多成年人，特别是高风险族群，仍然没有受到B型肝炎疫苗的保护。

治疗性疫苗的研发：治疗性B型肝炎疫苗的研究正在进行中，该疫苗可望治疗慢性B型肝炎感染。如果成功，这些疫苗将显着扩大市场规模，并彻底改变B型肝炎治疗的格局。

扩大新兴市场的疫苗生产：新兴市场，尤其是亚洲市场，正朝着提高疫苗生产能力的方向发展。这有助于降低疫苗成本，并提高这些地区的疫苗供应。

乙肝疫苗市场区域分析

乙肝疫苗市场区域分析

北美：

根据Verified Market Research的数据，预计北美将在预测期内主导乙肝疫苗市场。北美市场受益于各国政府透过全面的疫苗接种计画大力消除B型肝炎。例如，美国卫生与公众服务部实施了“病毒性肝炎国家战略计划（2021-2025）”，旨在降低肝炎感染对公共卫生的威胁。该计划提高了疫苗的可及性和覆盖率，显着促进了市场成长。美国疾病管制与预防中心（CDC）的数据显示，2021年，美国超过90%的婴儿在24个月大前接种了B型肝炎疫苗。

北美是乙肝流行率较高的地区，推动了疫苗接种的需求：光是在美国就有约120万人患有慢性B肝，美国疾病管制与预防中心估计，2019年将有22,000例急性B肝新发病例。这种高疾病负担正在推动疫苗和预防策略的采用率提高。

此外，预防多种疾病（包括B型肝炎）的联合疫苗的使用是北美的主要驱动力。像Pediarix（一种包含乙肝疫苗的五价疫苗）这样的疫苗的推出增加了市场占有率，尤其是在儿童疫苗领域。政府强调联合疫苗的免疫接种计划进一步支持了这一趋势。美国疾病管制与预防中心指出，为了提高免疫接种计画的依从性，联合疫苗的使用正在增加。

亚太地区：

预计亚太地区将在预测期内呈现最高成长。亚太地区是全球乙肝感染负担最重的地区之一，推动了对疫苗的需求。根据世界卫生组织 (WHO) 的数据，全球超过 60% 的乙肝病毒携带者居住在亚洲，其中中国占大多数。光是在中国，就有 7,000 万人患有慢性B肝，每年约有 100 万人死于B型肝炎相关併发症。如此高的病例数正推动该地区对疫苗的接受度。

亚太地区的国家免疫规划为B肝疫苗市场提供了强而有力的支持。例如，中国政府的免疫规划在出生后24小时内接种疫苗，儿童B肝疫苗接种率已超过90%。世界卫生组织2017年报告称，西太平洋地区约85%的国家已实施全民乙肝疫苗接种，感染率显着下降。

此外，製药公司与研究机构之间的持续合作也推动了亚太地区市场的成长。 2022年4月，日本製药公司盐野义製药株式会社与NEC株式会社合作，开发了一种针对B肝的新型疫苗，以治癒这种慢性感染疾病。在不断增长的研发投入的支持下，此类合作正在推动先进疫苗的开发，促进该地区市场的快速扩张。

目录

第一章 引言

• 市场定义
• 市场区隔
• 调查方法

第二章执行摘要

• 主要发现
• 市场概览
• 市集亮点

第三章市场概述

• 市场规模和成长潜力
• 市场趋势
• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析

4. 乙肝疫苗市场（依类型）

• 单一疫苗
• 联合疫苗

5. 乙肝疫苗市场（依患者类型）

• 成人
• 孩子们

6. 乙肝疫苗市场（依分销管道）

• 医院药房
• 零售药局
• 网路药局

第七章区域分析

• 北美洲
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 英国
• 德国
• 法国
• 义大利
• 亚太地区
• 中国
• 日本
• 印度
• 澳洲
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中东和非洲
• 南非
• 沙乌地阿拉伯
• 阿拉伯聯合大公国

第八章市场动态

• 市场驱动因素
• 市场限制
• 市场机会
• COVID-19 市场影响

第九章 竞争态势

• 主要企业
• 市场占有率分析

第十章 公司简介

• Merck & Co., Inc.
• GlaxoSmithKline plc.
• Sanofi Pasteur
• Walgreens Boots Alliance, Inc.
• Serum Institute of India Pvt. Ltd.
• China National Biotec Group Co., Ltd.
• F. Hoffmann-La Roche Ltd.
• Mylan NV
• Shionogi & Co., Ltd.
• Abbott Laboratories

第十一章 市场展望与机会

• 新兴技术
• 未来市场趋势
• 投资机会

第十二章 附录

• 简称列表
• 来源和参考文献

Hepatitis B Vaccines Market Size and Forecast

Hepatitis B Vaccines Market size was valued at USD 8.26 Billion in 2024 and is projected to reach USD 13.31 Billion by 2032, growing at a CAGR of 4.6 % from 2026 to 2032.

Hepatitis B vaccines are used to prevent infection caused by the hepatitis B virus, which leads to serious liver diseases including cirrhosis and hepatocellular carcinoma.

These vaccines work by stimulating the body's immune system to produce antibodies against the hepatitis B virus.

Furthermore, hepatitis B vaccines are widely used in national immunization programs for newborns and high-risk adult populations and are considered one of the most effective ways to prevent hepatitis B infection and its complications.

Hepatitis B Vaccines Market Dynamics

The key market dynamics that are shaping the hepatitis B vaccines market include:

Key Market Drivers

Rising Global Prevalence of Hepatitis B: The rising prevalence of Hepatitis B infections worldwide is a major driver of vaccination demand. According to the World Health Organization (WHO), around 296 million individuals were living with chronic Hepatitis B infection in 2019, with 1.5 million new infections happening annually. The increasing number of cases highlights the need for immunizations to prevent the disease from spreading further.

Government Immunization Programs: Many nations are extending their immunization programs to combat Hepatitis B infections, considerably increasing the market. For example, the CDC advises that in the United States, Hepatitis B immunization is recommended for all infants, unvaccinated children under the age of 19, and at-risk adults. In 2020, global baby vaccination coverage reached 85%, up from 30% in 2000.

Increasing Healthcare Awareness and Initiatives: Increased awareness of Hepatitis B and government-led health programs in emerging nations are promoting vaccination adoption. For example, China's National Health Commission started an attempt to lower the prevalence of chronic Hepatitis B by boosting immunization. According to 2020 research, more than 90% of children in China have had Hepatitis B vaccinations by the age of one, which is essential for market growth.

Key Challenges:

Vaccine Hesitancy: Despite the proven efficacy of hepatitis B vaccines, vaccine hesitancy remains a significant challenge in some regions. Misconceptions about vaccine safety and efficacy hinder uptake rates, potentially impacting market growth.

Cold Chain Management: Hepatitis B vaccines require strict temperature control during storage and transportation. Maintaining the cold chain, especially in resource-limited settings, poses logistical challenges that affect vaccine distribution and availability.

High Cost of New Vaccine Development: The development of new and improved hepatitis B vaccines involves substantial research and development costs. These high costs are a barrier to market entry for new players and limit innovation in the field.

Key Trends:

Increasing Focus on Adult Vaccination: While childhood vaccination programs are well-established, there is a growing emphasis on adult hepatitis B vaccination. This trend is driven by the recognition that many adults remain unprotected against hepatitis B, particularly in high-risk groups.

Development of Therapeutic Vaccines: Research is ongoing into therapeutic hepatitis B vaccines that could potentially treat chronic hepatitis B infections. If successful, these vaccines could significantly expand the market and change the landscape of hepatitis B treatment.

Expansion of Vaccine Production in Emerging Markets: There is a trend towards increasing vaccine production capabilities in emerging markets, particularly in Asia. This is helping to reduce vaccine costs and improve availability in these regions.

Hepatitis B Vaccines Market Regional Analysis

The regional analysis of the hepatitis B vaccines market:

North America:

According to Verified Market Research, North America is estimated to dominate the hepatitis B vaccines market over the forecast period. The North American market benefits from strong governmental efforts to eliminate hepatitis B through comprehensive vaccination programs. For instance, the U.S. Department of Health & Human Services implemented the "Viral Hepatitis National Strategic Plan (2021-2025)" aimed at reducing hepatitis infections as a public health threat. This plan enhances vaccine accessibility and coverage, contributing significantly to the market's growth. According to the CDC, in 2021, over 90% of U.S. infants received the hepatitis B vaccine by 24 months of age.

North America has a notable prevalence of hepatitis B, which drives the demand for vaccination. In the United States alone, approximately 1.2 million people are chronically infected with hepatitis B. The CDC highlights that 22,000 new acute hepatitis B cases were estimated in 2019. This high disease burden prompts increased adoption of vaccines and preventive strategies.

Furthermore, the use of combination vaccines that protect against multiple diseases, including hepatitis B, is a key driver in North America. The introduction of vaccines like Pediarix (a 5-in-1 vaccine that includes hepatitis B) has expanded the market share, particularly in pediatric vaccinations. This trend is further supported by government-backed vaccination schedules that emphasize combination vaccines. The CDC notes that combination vaccines are increasingly used to improve adherence to immunization programs.

Asia Pacific:

The Asia Pacific region is estimated to exhibit the highest growth during the forecast period. The Asia-Pacific region has one of the highest burdens of Hepatitis B infections globally, driving the demand for vaccines. According to the World Health Organization (WHO), more than 60% of the world's Hepatitis B carriers live in Asia, with China accounting for a large portion. In China alone, 70 million people are chronically infected, and around 1 million people die each year due to Hepatitis B-related complications. This significant patient population fuels vaccine adoption across the region.

National immunization programs in Asia-Pacific are strongly supporting the hepatitis B vaccine market. For example, the Chinese government's immunization program has achieved over 90% Hepatitis B vaccine coverage among children, with a birth dose administered within 24 hours of birth. In 2017, WHO reported that around 85% of countries in the Western Pacific Region implemented universal Hepatitis B immunization, leading to a significant reduction in infection rates.

Furthermore, ongoing collaborations between pharmaceutical companies and research institutions are driving market growth in Asia-Pacific. In April 2022, Japanese pharmaceutical company Shionogi & Co., Ltd. partnered with NEC Corporation to develop a novel vaccine targeting Hepatitis B, aimed at curing chronic infections. These collaborations, supported by growing R&D investments, are boosting the development of advanced vaccines, contributing to the rapid market expansion in the region.

Hepatitis B Vaccines Market: Segmentation Analysis

The Hepatitis B Vaccines Market is segmented based on Type, Patient Type, Distribution Channel, and Geography.

Hepatitis B Vaccines Market, By Type

• Mono Vaccines
• Combination Vaccines

Based on Type, the market is segmented into Mono Vaccines and Combination Vaccines. The combination vaccines segment is estimated to dominate the hepatitis B vaccines market due to its ability to protect against multiple diseases in a single shot. These vaccines, which typically combine hepatitis B protection with other antigens such as those for diphtheria, tetanus, and pertussis, are increasingly preferred in national immunization programs. The convenience of fewer injections for patients and healthcare providers, along with reduced administration costs, are key factors driving the popularity of combination vaccines. While mono vaccines remain important, particularly for adult vaccination, the efficiency and cost-effectiveness of combination vaccines are cementing their dominant position in the market.

Hepatitis B Vaccines Market, By Patient Type

• Adult
• Pediatric

Based on Patient Type, the market is segmented into Adult and Pediatric. The pediatric segment is estimated to grow at the highest CAGR in the hepatitis B vaccines market. This growth is primarily driven by the widespread implementation of universal hepatitis B vaccination programs for newborns and infants in many countries. These programs, recommended by the World Health Organization, aim to prevent mother-to-child transmission and early childhood infections. The high birth rates in developing countries, coupled with increasing awareness about the importance of early vaccination, are fueling the growth of the pediatric segment. While adult vaccination remains crucial, especially for high-risk groups, the focus on preventing hepatitis B infection from the earliest stages of life is expected to maintain the pediatric segment's dominant position in the market.

Hepatitis B Vaccines Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Based on the Distribution Channel, the market is divided into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The hospital pharmacies segment is estimated to dominate the market over the forecast period. This dominance is attributed to the fact that a significant portion of hepatitis B vaccinations are administered in hospital settings, particularly for newborns and high-risk patients. Hospitals are often the primary sites for implementing national immunization programs, especially for infant vaccinations. Additionally, hospital pharmacies are well-equipped to handle the storage and distribution requirements of vaccines, including maintaining the cold chain. The trend towards combination vaccines, which are often administered as part of comprehensive immunization schedules in hospital settings, further reinforces the dominance of the hospital pharmacies segment.

Hepatitis B Vaccines Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

Based on Geography, the hepatitis B vaccines market is classified into North America, Based on geography, the Hepatitis B Vaccines Market is classified into North America, Europe, Asia-Pacific, and the Rest of the World. The North American region is expected to dominate the market during the forecast period due to several key factors. A high prevalence of hepatitis B in the United States, with approximately 1.2 million people chronically infected, drives a strong demand for vaccines. Additionally, comprehensive immunization programs such as the U.S. Department of Health & Human Services' "Viral Hepatitis National Strategic Plan (2021-2025)" aim to increase vaccine coverage across all population groups. The region's strong healthcare infrastructure and significant investments in vaccine development also contribute to this market leadership.

Key Players

• The "Hepatitis B Vaccines Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are GlaxoSmithKline plc, Merck & Co., Inc., Sanofi Pasteur, Dynavax Technologies Corporation, LG Chem, Serum Institute of India, Bharat Biotech, Biological E Limited, Crucell (Johnson & Johnson), and VBI Vaccines Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Hepatitis B Vaccines Market Recent Developments
• In September 2023, Dynavax Technologies Corporation announced that positive Phase 1 clinical trial results had been obtained for its next-generation hepatitis B vaccine candidate. The vaccine demonstrated a favorable safety profile and robust immune responses, potentially offering improved protection against hepatitis B.
• In March 2023, Sanofi Pasteur launched a new hexavalent vaccine in Europe that protects against six diseases, including hepatitis B. This combination vaccine is designed to simplify childhood immunization schedules and improve vaccination coverage.
• In December 2022, the World Health Organization prequalified a new pediatric hepatitis B vaccine developed by LG Chem. This prequalification allows the vaccine to be procured by UN agencies and Gavi, the Vaccine Alliance, for use in global immunization programs.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Hepatitis B Vaccines Market, By Type

• Mono Vaccines
• Combination Vaccines

5. Hepatitis B Vaccines Market, By Patient Type

• Adult
• Pediatric

6. Hepatitis B Vaccines Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Merck & Co., Inc.
• GlaxoSmithKline plc.
• Sanofi Pasteur
• Walgreens Boots Alliance, Inc.
• Serum Institute of India Pvt. Ltd.
• China National Biotec Group Co., Ltd.
• F. Hoffmann-La Roche Ltd.
• Mylan N.V.
• Shionogi & Co., Ltd.
• Abbott Laboratories

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References